Humana (NYSE:HUM) Price Target Raised to $301.00 at Morgan Stanley

Humana (NYSE:HUM - Get Free Report) had its price objective upped by equities research analysts at Morgan Stanley from $288.00 to $301.00 in a research note issued on Tuesday,Benzinga reports. The firm presently has an "equal weight" rating on the insurance provider's stock. Morgan Stanley's target price suggests a potential upside of 28.69% from the company's previous close.

Several other research firms also recently issued reports on HUM. Wells Fargo & Company decreased their price target on Humana from $387.00 to $290.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. Deutsche Bank Aktiengesellschaft cut their price target on Humana from $349.00 to $250.00 and set a "hold" rating for the company in a report on Thursday, October 3rd. Cantor Fitzgerald restated a "neutral" rating and set a $395.00 price target on shares of Humana in a research note on Tuesday, October 1st. Royal Bank of Canada dropped their price objective on Humana from $400.00 to $265.00 and set an "outperform" rating for the company in a research note on Tuesday, October 8th. Finally, UBS Group lowered their target price on shares of Humana from $380.00 to $250.00 and set a "neutral" rating on the stock in a report on Friday, October 4th. Twenty research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $300.50.

Humana Price Performance

HUM stock traded down $26.57 during trading on Tuesday, hitting $233.89. The company had a trading volume of 5,639,765 shares, compared to its average volume of 1,862,571. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $475.00. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $28.16 billion, a price-to-earnings ratio of 21.53, a P/E/G ratio of 2.15 and a beta of 0.53. The business has a 50 day moving average of $274.62 and a 200 day moving average of $323.77.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share for the quarter, topping the consensus estimate of $3.48 by $0.68. The firm had revenue of $29.30 billion for the quarter, compared to analysts' expectations of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, research analysts predict that Humana will post 16.14 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in HUM. Oddo BHF Asset Management Sas bought a new position in shares of Humana during the third quarter worth about $1,306,000. Synovus Financial Corp boosted its holdings in shares of Humana by 4.1% during the 3rd quarter. Synovus Financial Corp now owns 2,254 shares of the insurance provider's stock worth $714,000 after buying an additional 89 shares during the period. Tidal Investments LLC increased its stake in shares of Humana by 38.4% during the third quarter. Tidal Investments LLC now owns 24,357 shares of the insurance provider's stock worth $7,715,000 after purchasing an additional 6,755 shares during the period. Wilmington Savings Fund Society FSB acquired a new stake in Humana during the 3rd quarter worth approximately $948,000. Finally, Virtu Financial LLC bought a new stake in Humana in the 3rd quarter valued at $631,000. 92.38% of the stock is currently owned by institutional investors.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.